Overview

This trial is active, not recruiting.

Conditions guillain-barre syndrome, cidp, multifocal motor neuropathy
Sponsor University of Cologne
Start date October 2012
End date December 2014
Trial size 50 participants
Trial identifier NCT01655394, 01607831337

Summary

IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
Clinical Improvement
time frame: 6 Months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - immune neuropathy - age above 18 y - IVIg treatment exclusion: - no IVIg treatment

Additional Information

Official title Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
Principal investigator Helmar C. Lehmann, PD Dr. med.
Description IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored
Trial information was received from ClinicalTrials.gov and was last updated in December 2014.
Information provided to ClinicalTrials.gov by University of Cologne.